Table 1.
Clinical Trials Therapeutically Targeting MDSCs.
| Mechanism | Trial Title | Intervention(s) | Trial No./referencea |
|---|---|---|---|
| Depletion | Dendritic cell vaccine with or without gemcitabine pre-treatment for adults and children with sarcoma | Dendritic cell vaccine, lysate of tumor, gemcitabine, imiquimod |
NCT01803152 (78) |
| Depletion | PDE5 inhibition via tadalafil to enhance anti-tumor mucin 1 (MUC1) vaccine efficacy in patients with HNSCC | Tadalafil, anti-MUC1 vaccine |
NCT02544880 (79, 80) |
| Depletion | A Study of RGX-104 in patients with advanced solid malignancies and lymphoma | RGX-104, nivolumab, ipilimumab, docetaxel, pembrolizumab, carboplatin, pemetrexed |
NCT02922764 (81, 82) |
| Depletion | GTB-3550 (CD16/IL-15/CD33) tri-specific killer engager (TriKE™) for high risk heme malignancies | GTB-3550 TriKE |
NCT03214666 (83) |
| Signaling | Ibrutinib and nivolumab in treating participants with metastatic solid tumors | Ibrutinib, nivolumab |
NCT03525925 (84) |
| Signaling | Histamine receptor 2 antagonists as enhancers of anti-tumor immunity | Ranitidine |
NCT03145012 (85) |
| Signaling | Myeloid-derived suppressor cells (MDSCs) in OSCC patients | β-glucan |
NCT04387682 (86) |
| Signaling | VX15/2503 in combination with ipilimumab or nivolumab in patients with head and neck cancer | VX15/2503, nivolumab, ipilimumab |
NCT03690986 (87, 88) |
| Maturation | Ipilimumab and all-trans retinoic acid combination treatment of advanced melanoma | VESANOID, ipilimumab |
NCT02403778 (89) |
| Maturation | Pembrolizumab and all-trans retinoic acid combination treatment of advanced melanoma | Pembrolizumab with all-trans retinoic acid |
NCT03200847 (89) |
| Transcription | A study of MTL-CEBPA in combination with a PD-1 inhibitor in patients with advanced solid tumors (TIMEPOINT) | MTL-CEBPA, pembrolizumab |
NCT04105335 (90) |
a
Reference refers to the original publication(s) that supported the rationale for the indicated clinical trial.